Product

The first Tumor Paint product candidate, BLZ-100, is being developed for cancer surgery in multiple solid tumor types. BLZ-100 is a drug administered by IV injection that circulates within the body and “lights up” cancer cells. It consists of a peptide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range.

BLZ-100 has been tested in four Phase 1 clinical trials and has demonstrated clinical proof of concept in brain, breast and skin cancers. Preclinical utility of BLZ-100 has been demonstrated in prostate, lung, colorectal, and other solid tumor cancers.

BLZ-100, an investigational agent, is being evaluated in a Phase 2/3 clinical study in pediatric CNS (central nervous system) tumors.